Answers are grounded in this paper and cite their sources.
BACKGROUND: The treatment of NTM pulmonary disease is hindered by scarce therapeutic options. Bedaquiline is a diarylquinoline with activity against Mycobacterium tuberculosis and a variety of pathogenic nontuberculous mycobacteria (NTM) that could help fill this unmet need, but clinical data are needed to support its use. METHODS: We retrospectively reviewed the use of bedaquiline in patients with NTM pulmonary disease from National Jewish Health and the University of Texas Health Science Center Tyler between the years of 2013 and 2022. RESULTS: Eighty-seven patients were included in the study. Most patients were female (66/87, 75.8%) and the mean age was 55 years. 54% had cavitary lung disease. People with cystic fibrosis made up 26.4% of the cohort. There were 46 patients with Mycobacterium avium complex, 36 patients with Mycobacterium abscessus and five patients with other mycobacterial infections. 64% of isolates had macrolide resistance, either inducible or mutational, 31% had amikacin resistance (MIC ≥ 64 𝜇g/ml) and 21.8% had both macrolide and amikacin resistance. The mean duration of antibiotic use prior to the initiation of bedaquiline was 32.8 months (0-165 months). The most common indication for bedaquiline use was treatment failure related to intolerance or resistance to antibiotics. Mean duration of bedaquiline use was 20 months (range 1-134 mos.). Bedaquiline was well tolerated: only 10% (9/87) of patients required discontinuation of treatment related to side effects of whom 4 reported adverse events related to bedaquiline, one with a rash, one with nausea and two with transaminase elevation. None of the patients discontinued therapy related to QTc prolongation. Ten patients had to discontinue bedaquiline due to lack of insurance coverage, although the mean exposure to bedaquiline in this group was 18 months (2-43 mo.) Once on bedaquiline, 46% had sputum cultures convert to negative (defined as two negative cultures over three months) and 40% were able to discontinue all therapy with 12 months of negative cultures. CONCLUSION: In this cohort of treatment experienced patients with drug resistance or intolerance, bedaquiline was well-tolerated and led to cure in 40% of patients.
No takes yet. Share an insight, caveat, or question.
Kasperbauer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: